TheraRadar
Data updated: May 26, 2026

GOPRELTO (cocaine hydrochloride)

Other Approved 2017-12-14

GOPRELTO is indicated for the treatment of Local Anesthesia.

Source: FDA Label • LXO IRELAND
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2017-12-14
Patent Cliff
2037

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
NASAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: COCAINE HYDROCHLORIDE

GOPRELTO Approval History

2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2017 to 2023
Jul 2023 SUPPL
Label · Labeling
Nov 2022 SUPPL
Label · Labeling
Dec 2017 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What GOPRELTO Treats

1 indications

GOPRELTO is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Local Anesthesia
Source: FDA Label

GOPRELTO Boxed Warning

ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [see Warning and Precautions (5.1) . ] WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (5.1)...

GOPRELTO Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 5 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to GOPRELTO

3 of 4

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
EPINEPHRINE BITARTRATE
1 shared
Baxter
Shared indications:
Local anesthesia
NESACAINE-MPF
CHLOROPROCAINE HYDROCHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Local Anesthesia
NUMBRINO
COCAINE HYDROCHLORIDE
1 shared
OMNIVIUM PHARMS
Shared indications:
Local Anesthesia
📋

Clinical Trial Registry

6 trials
Trial Sponsor ID Phase Status Title
NCT06273540 STA-P7-C001 C-043-2023 Ph 1 completed Phase1, STP7 Cocaine Drug-Drug Interaction Study
NCT02302976 1409014655 1R21DA040914-01A1 Ph 1 completed GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
NCT01978431 1001006250 R25MH071584 Ph 1 completed Impulsivity and Stimulant Administration
NCT02018263 1212011268 Ph 1 completed Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
NCT01978457 1104008404 Ph 1 terminated Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
NCT01137890 results posted R01DA027065 R01DA027065 Ph 1, Ph 2 completed Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GOPRELTO FDA Label Details

Indications & Usage

FDA Label (PDF)

GOPRELTO is indicated for the treatment of Local Anesthesia.

⚠️ BOXED WARNING

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [see Warning and Precautions (5.1) . ] WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. CNS stimulants, including cocaine hydrochlor...

View full patent landscape →
12 OB patents · 3 families · 16 international docs across 1 countries

GOPRELTO Patents & Exclusivity

Latest Patent: Feb 2037

Patents (12 active)

US10016407 Expires Feb 7, 2037
US9867815 Expires Feb 7, 2037
US10413505 Expires Feb 7, 2037
US10420760 Expires Feb 7, 2037
US10149843 Expires Feb 7, 2037
US10933060 Expires Feb 7, 2037
US10973811 Expires Feb 7, 2037
US10987347 Expires Feb 7, 2037
US10894012 Expires Feb 7, 2037
US10857095 Expires Feb 7, 2037
US10231961 Expires Feb 7, 2037
US11040032 Expires Feb 7, 2037
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for GOPRELTO

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2037
  • 15 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 4 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.